{
  "docId": "019de074-15c9-703f-ba69-83bd63385db9",
  "docSlug": "61dc585c6c50f6919636d426c025da60",
  "documentTitle": "AstraZeneca | Investor Event Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 42,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 8,
  "notes": "Includes Kaplan-Meier survival curve and key efficacy metrics.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-15c9-703f-ba69-83bd63385db9/31",
  "deckHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9",
  "deckJsonHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9.json",
  "deckAnchorHref": "/decks/019de074-15c9-703f-ba69-83bd63385db9#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.3,
        "x": 0.67,
        "y": 0.075
      },
      "kind": "callout",
      "text": "Enhertu significantly reduced risk of death by 36% (HR, 0.64)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "789f5afb-e54b-4e52-b7d5-8c66200fe2a1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.6,
        "x": 0.03,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Kaplan-Meier overall survival curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d38554cf-6d59-46c9-b563-60b8f8440251",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.67,
        "y": 0.035
      },
      "kind": "list",
      "text": "mPFS with Enhertu 4x longer than T-DM1 (28.8m vs. 6.8m); 78.5% of patients experienced confirmed objective response; 1 in 5 (21.1%) of patients experienced complete response",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b90683ef-de95-4204-aa8b-18406f2b0481",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.03,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1 transtuzumab + pertuzumab + taxane (Swain SM et al. N Engl J Med. 2015; 372: 724-34); HER2 = human epidermal growth receptor 2; T-DM1 = Ado-trastuzumab emtansine; HR = hazard ratio; T-DxD = trastuzumab deruxtecan; mFPS = median progression free survival.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7659740d-8a56-48eb-8da7-70e5fe4841d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Reinforces Enhertu as established standard of care in 2L HER2-high",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d416c899-8706-4762-b44a-202475f5119e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Enhertu DESTINY-Breast03",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4f85e7a1-d677-48ce-b549-5b20ca57b8f5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 37,
      "from": 30,
      "beatId": "88b7703b-c29f-499c-87c5-dd04e5a0e55a",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Other key data, Enhertu, and capivasertib",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}